Introduction: Polymorphisms of the different genes have been reported to be associated with a variety of cancers including breast cancer. CYP genes belongings to Cytochrome P450 (CYP450), have been implicated in various cancer formation and development due to their roles such as oxidative stress, activating procarcinogens, and inactivating anticancer drugs. Objective: This study aimed to examine whether polymorphisms in the CYP3A4 and CYP3A5 genes affect the risk of developing breast cancer. Results: CYP3A4*1B gene polymorphism revealed that in breast cancer patient group 96 had the *1A/*1A genotype (64%), 39 (26%) had the *1A/*B genotype and 15 (10%) had the *1B/*B genotype. In the control group 131 (87%) had the *1A/*1A genotype, 16 (10.66%) had the *1A/*B genotype and 3 (2%) had the *1B/*B genotype. Concerning genotype distribution, a significant difference between the breast cancer patients and the controls was observed where p<0.05) The genotype frequency of the CYP3A5*3 *1/*1, *1/*3, and *3/*3 polymorphisms in breast cancer and healthy control group were analysed. Frequencies of CYP3A4*3 *1/*1, *1/*3 and *3/*3 genotypes were 67.3%, 24% and 8.7 % in breast cancer patients and 79.3%, 14% and 6.7% in the controls, respectively. The distribution of CYP3A5*3 *1/*3 genotypes was significantly associated with breast cancer patients when compared with controls. Conclusion: In conclusion, the results of our study found a positive association between CYP 3A4*1B and CYP3A5*3 polymorphisms and predispositions to breast cancer risk.